Claire Mazumdar
Known title: Chief Executive OfficerCIK: 0002034671
Associated companies
Transaction History
| BCAX | ▲ Buy | Option Exercise | 10,000 | $38K | 8/10/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 10,000 | $280K | 8/10/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 10,000 | $38K | 7/10/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 28 | $831 | 7/10/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 9,972 | $283K | 7/10/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 15,000 | $57K | 5/18/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 12,022 | $240K | 5/18/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 2,978 | $61K | 5/18/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 15,000 | $57K | 4/20/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 15,000 | $354K | 4/20/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 8,226 | $36K | 4/16/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 7,454 | $28K | 4/16/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 7,080 | $39K | 4/16/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 1,596 | $6K | 3/20/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 1,596 | $30K | 3/20/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 6,905 | $26K | 3/19/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 6,905 | $130K | 3/19/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 6,499 | $25K | 3/18/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 6,499 | $122K | 3/18/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 36,766 | $139K | 3/9/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 36,766 | $705K | 3/9/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 3,817 | $14K | 3/6/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 3,817 | $72K | 3/6/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 1,786 | $7K | 3/5/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 1,786 | $33K | 3/5/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 2,631 | $10K | 3/4/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 2,631 | $49K | 3/4/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 29,500 | $161K | 12/16/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 41,163 | $156K | 11/24/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 41,163 | $776K | 11/24/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 24,103 | $91K | 10/16/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 24,103 | $454K | 10/16/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 13,289 | $50K | 10/15/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 13,289 | $250K | 10/15/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 11,445 | $43K | 10/13/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 11,445 | $217K | 10/13/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BCAX flagged as potentially overvalued on book value
A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.
BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.